Discovery and optimization of peptide macrocycles

Expert Opinion on Drug Discovery

Volumn 11, Issue 12, 2016, Pages 1151-1163

  White, Andrew M ^a   Craik, David J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cyclic peptides; cyclotides; drug design; kalata B1; peptide macrocycles; stapled peptides

Indexed keywords

AMINO ACID; CYCLOPEPTIDE; CYCLOTIDE; DEFENSIN; EPITOPE; MACROCYCLIC COMPOUND; ORBITIDE DERIVATIVE; PEPTIDE DERIVATIVE; PEPTIDE MACROCYCLE DERIVATIVE; UNCLASSIFIED DRUG;

BETA HAIRPIN; BIOLOGICAL ACTIVITY; BIOMIMETICS; CLINICAL TRIAL (TOPIC); CYCLIZATION; DRUG BIOAVAILABILITY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG STABILITY; HUMAN; MEDICAL TECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN STRUCTURE; REVIEW; ANIMAL; CHEMISTRY; DRUG DESIGN; DRUG DEVELOPMENT; PHARMACEUTICS; PROCEDURES; PROTEIN DEGRADATION;

AMINO ACIDS; ANIMALS; CYCLIZATION; DRUG DESIGN; DRUG DISCOVERY; HUMANS; PEPTIDES, CYCLIC; PROTEOLYSIS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84994607957     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1080/17460441.2016.1245720     Document Type: Review

References (138)

1. F.Giordanetto, J.Kihlberg Macrocyclic drugs and clinical candidates:what can medicinal chemists learn from their properties? J Med Chem. 2014;57:278–295. DOI:10.1021/jm400887j
2. C.A.Lipinski. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000;44:235–249. DOI:10.1016/S1056-8719(00)00107-6• A paper defining five key rules used in medicinal chemistry to guide the development of orally active small-molecule drugs.
3. D.F.Veber, S.R.Johnson, H.Y.Cheng, et al. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45:2615–2623. DOI:10.1021/jm020017n• A paper defining the molecular properties that influence oral bioavailability independent of molecule size.
4. D.J.Craik, D.P.Fairlie, S.Liras, et al. The future of peptide‐based drugs. Chem Biol Drug Des. 2013;81:136–147. DOI:10.1111/cbdd.12055• A review highlighting the challenges and future directions of peptides as drugs.
5. S.E.Northfield, C.K.Wang, C.I.Schroeder, et al. Disulfide-rich macrocyclic peptides as templates in drug design. Euro J Med Chem. 2014;77:248–257. DOI:10.1016/j.ejmech.2014.03.011
6. T.K.Sawyer, V.Guerlavais, K.Darlak, et al. Macrocyclic α-helical peptide drug discovery. In:Levin J, editor. Macrocycles in drug discovery. London:RSC Drug Discovery Series; 2015. p. 339–366.
7. M.Montalban-Lopez, M.Sanchez-Hidalgo, R.Cebrian, et al. Discovering the bacterial circular proteins:bacteriocins, cyanobactins, and pilins. J Biol Chem. 2012;287:27007–27013. DOI:10.1074/jbc.R112.354688
8. U.Göransson, R.Burman, S.Gunasekera, et al. Circular proteins from plants and fungi. J Biol Chem. 2012;287:27001–27006. DOI:10.1074/jbc.R111.300129
9. R.I.Lehrer, A.M.Cole, M.E.Selsted. θ-Defensins:cyclic peptides with endless potential. J Biol Chem. 2012;287:27014–27019. DOI:10.1074/jbc.R112.346098
10. H.Luo, S.Y.Hong, R.M.Sgambelluri, et al. Peptide macrocyclization catalyzed by a prolyl oligopeptidase involved in alpha-amanitin biosynthesis. Chem Biol. 2014;21:1610–1617. DOI:10.1016/j.chembiol.2014.10.015
11. C.W.Gruber, A.G.Elliott, D.C.Ireland, et al. Distribution and evolution of circular miniproteins in flowering plants. Plant Cell. 2008;20:2471–2483. DOI:10.1105/tpc.108.062331
12. K.Sletten, L.Gran. Some molecular properties of kalatapeptide B-1. A uterotonic polypeptide isolated from Oldenlandia affinis DC. Medd Nor Farm Selsk. 1973;7:69–82.
13. D.J.Craik, N.L.Daly, T.Bond, et al. Plant cyclotides:A unique family of cyclic and knotted proteins that defines the cyclic cystine knot structural motif. J Mol Biol. 1999;294:1327–1336. DOI:10.1006/jmbi.1999.3383• The original paper defining the cyclotide family of peptides.
14. C.K.L.Wang, K.Quentin, L.Chiche, et al. CyBase:A database of cyclic protein sequences and structures, with application in protein discovery and engineering. Nucleic Acids Res. 2008;36:D206–210. DOI:10.1093/nar/gkm953
15. M.L.Colgrave, D.J.Craik. Thermal, chemical, and enzymatic stability of the cyclotide Kalata B1:the importance of the cyclic cystine knot. Biochemistry. 2004;43:5965–5975. DOI:10.1021/bi049711q
16. N.L.Daly, K.R.Gustafson, D.J.Craik. The role of the cyclic peptide backbone in the anti-HIV activity of the cyclotide kalata B1. FEBS Lett. 2004;574:69–72. DOI:10.1016/j.febslet.2004.08.007
17. M.E.Felizmenio-Quimio, N.L.Daly, D.J.Craik. Circular proteins in plants:solution structure of a novel macrocyclic trypsin inhibitor from Momordica cochinchinensis. J Biol Chem. 2001;276:22875–22882. DOI:10.1074/jbc.M101666200
18. L.Chiche, A.Heitz, J.C.Gelly, et al. Squash inhibitors:from structural motifs to macrocyclic knottins. Curr Protein Pept Sci. 2004;5:341–349. DOI:10.2174/1389203043379477
19. K.R.Gustafson, L.K.Walton, R.C.SowderJr., et al. New circulin macrocyclic polypeptides from Chassalia parvifolia. J Nat Prod. 2000;63:176–178. DOI:10.1021/np990432r
20. J.P.Tam, Y.A.Lu, J.L.Yang, et al. An unusual structural motif of antimicrobial peptides containing end-to-end macrocycle and cystine-knot disulfides. Proc Natl Acad Sci USA. 1999;96:8913–8918. DOI:10.1073/pnas.96.16.8913
21. D.C.Ireland, M.L.Colgrave, D.J.Craik. A novel suite of cyclotides from Viola odorata:Sequence variation and the implications for structure, function and stability. Biochem J. 2006;400:1–12. DOI:10.1042/bj20060627
22. M.R.Plan, U.Göransson, R.J.Clark, et al. The cyclotide fingerprint in oldenlandia affinis:elucidation of chemically modified, linear and novel macrocyclic peptides. ChemBioChem. 2007;8:1001–1011. DOI:10.1002/cbic.200700097
23. S.M.Simonsen, L.Sando, K.J.Rosengren, et al. Alanine scanning mutagenesis of the prototypic cyclotide reveals a cluster of residues essential for bioactivity. J Biol Chem. 2008;283:9805–9813. DOI:10.1074/jbc.M709303200
24. P.Lindholm, U.Göransson, S.Johansson, et al. Cyclotides:A novel type of cytotoxic agents. Mol Cancer Ther. 2002;1:365–369.
25. S.L.Gerlach, R.Rathinakumar, G.Chakravarty, et al. Anticancer and chemosensitizing abilities of cycloviolacin 02 from Viola odorata and psyle cyclotides from Psychotria leptothyrsa. Biopolymers. 2010;94:617–625. DOI:10.1002/bip.21435
26. C.Jennings, J.West, C.Waine, et al. Biosynthesis and insecticidal properties of plant cyclotides:the cyclic knotted proteins from Oldenlandia affinis. Proc Natl Acad Sci USA. 2001;98:10614–10619. DOI:10.1073/pnas.191366898
27. M.L.Colgrave, A.C.Kotze, D.C.Ireland, et al. The anthelmintic activity of the cyclotides:natural variants with enhanced activity. ChemBioChem. 2008;9:1939–1945. DOI:10.1002/cbic.200800174
28. M.R.Plan, I.Saska, A.G.Cagauan, et al. Backbone cyclised peptides from plants show molluscicidal activity against the rice pest Pomacea canaliculata (golden apple snail). J Agric Food Chem. 2008;56:5237–5241. DOI:10.1021/jf800302f
29. B.L.Barbeta, A.T.Marshall, A.D.Gillon, et al. Plant cyclotides disrupt epithelial cells in the midgut of lepidopteran larvae. Proc Natl Acad Sci USA. 2008;105:1221–1225. DOI:10.1073/pnas.0710338104
30. N.L.Daly, R.J.Clark, D.J.Craik. Disulfide folding pathways of cystine knot proteins. Tying the knot within the circular backbone of the cyclotides. J Biol Chem. 2003;278:6314–6322. DOI:10.1074/jbc.M210492200
31. U.Göransson, D.J.Craik. Disulfide mapping of the cyclotide kalata B1. Chemical proof of the cystic cystine knot motif. J Biol Chem. 2003;278:48188–48196. DOI:10.1074/jbc.M308771200
32. O.Cheneval, C.I.Schroeder, T.Durek, et al. Fmoc-based synthesis of disulfide-rich cyclic peptides. J Org Chem. 2014;79:5538–5544. DOI:10.1021/jo500699m•• A paper outlining a protocol for the efficient synthesis of disulfide rich cyclic peptides.
33. R.J.Clark, N.L.Daly, D.J.Craik. Structural plasticity of the cyclic-cystine-knot framework:implications for biological activity and drug design. Biochem J. 2006;394:85–93. DOI:10.1042/BJ20051691
34. Y.Ji, S.Majumder, M.Millard, et al. In vivo activation of the p53 tumor suppressor pathway by an engineered cyclotide. J Am Chem Soc. 2013;135:11623–11633. DOI:10.1021/ja405108p•• A paper reporting the development of a stable engineered cyclotide that antagonizes the intracellular p53 tumor suppressor pathway with nanomolar affinity, both in vitro and in vivo.
35. C.D’Souza, S.T.Henriques, C.K.Wang, et al. Using the MCoTI-II cyclotide scaffold to design a stable cyclic peptide antagonist of SET, a protein overexpressed in human cancer. Biochemistry. 2016;55:396–405. DOI:10.1021/acs.biochem.5b00529
36. C.K.Wang, C.W.Gruber, M.Cemazar, et al. Molecular grafting onto a stable framework yields novel cyclic peptides for the treatment of multiple sclerosis. ACS Chem Biol. 2014;9:156–163. DOI:10.1021/cb400548s• A paper describing the stabilization of a myelin oligodendrocyte glycoprotein epitope grafted into a cyclotide and the subsequent inhibition of multiple sclerosis in mice.
37. C.T.T.Wong, D.K.Rowlands, C.H.Wong, et al. Orally active peptidic bradykinin B1 receptor antagonists engineered from a cyclotide scaffold for inflammatory pain treatment. Angew Chem Int Ed. 2012;51:5620–5624. DOI:10.1002/anie.201200984
38. Y.H.Huang, S.T.Henriques, C.K.Wang, et al. Design of substrate-based BCR-ABL kinase inhibitors using the cyclotide scaffold. Sci Rep. 2015;5:12974. DOI:10.1038/srep12974• A paper reporting the design of an engineered cyclotide with inhibitory activity of BCR-ABL tyrosine kinase for the treatment of chronic myeloid leukemia.
39. T.Aboye, C.J.Meeks, S.Majumder, et al. Design of a MCoTI-based cyclotide with angiotensin (1-7)-like activity. Molecules. 2016;21. DOI:10.3390/molecules21020152
40. R.Eliasen, N.L.Daly, B.S.Wulff, et al. Design, synthesis, structural and functional characterization of novel melanocortin agonists based on the cyclotide kalata B1. J Biol Chem. 2012;287:40493–40501. DOI:10.1074/jbc.M112.395442
41. L.Y.Chan, S.Gunasekera, S.T.Henriques, et al. Engineering pro-angiogenic peptides using stable, disulfide-rich cyclic scaffolds. Blood. 2011;118:6709–6717. DOI:10.1182/blood-2011-06-359141
42. K.Thell, R.Hellinger, E.Sahin, et al. Oral activity of a nature-derived cyclic peptide for the treatment of multiple sclerosis. Proc Natl Acad Sci USA. 2016;113:3960–3965. DOI:10.1073/pnas.1519960113•• A study demonstrating the oral activity of an engineered cyclotide that silences T cell proliferation as an immunosuppressive molecule for the treatment of multiple sclerosis.
43. K.P.Greenwood, N.L.Daly, D.L.Brown, et al. The cyclic cystine knot miniprotein MCoTI-II is internalized into cells by macropinocytosis. Int J Biochem Cell Biol. 2007;39:2252–2264. DOI:10.1016/j.biocel.2007.06.016
44. L.Cascales, S.T.Henriques, M.C.Kerr, et al. Identification and characterization of a new family of cell-penetrating peptides:cyclic cell-penetrating peptides. J Biol Chem. 2011;286:36932–36943. DOI:10.1074/jbc.M111.264424
45. J.Contreras, A.Y.O.Elnagar, S.F.Hamm-Alvarez, et al. Cellular uptake of cyclotide MCoTI-I follows multiple endocytic pathways. J Control Release. 2011;155:134–143. DOI:10.1016/j.jconrel.2011.08.030
46. S.T.Henriques, Y.H.Huang, S.Chaousis, et al. The prototypic cyclotide Kalata B1 has a unique mechanism of entering cells. Chem Biol. 2015;22:1087–2097. DOI:10.1016/j.chembiol.2015.07.012• A paper describing the mechanism of cellular penetration of the cyclotide kalata B1.
47. C.D’Souza, S.T.Henriques, C.K.Wang, et al. Structural parameters modulating the cellular uptake of disulfide-rich cyclic cell-penetrating peptides:MCoTI-II and SFTI-1. Euro J Med Chem. 2014;88:10–18. DOI:10.1016/j.ejmech.2014.06.047
48. G.K.T.Nguyen, S.Wang, Y.Qiu, et al. Butelase 1 is an Asx-specific ligase enabling peptide macrocyclization and synthesis. Nat Chem Biol. 2014;10:732–738. DOI:10.1038/nchembio.1586
49. K.S.Harris, T.Durek, Q.Kaas, et al. Efficient backbone cyclization of linear peptides by a recombinant asparaginyl endopeptidase. Nat Commun. 2015;6. DOI:10.1038/ncomms10199
50. Y.Q.Tang, J.Yuan, G.Osapay, et al. A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated alpha-defensins. Science. 1999;286:498–502. DOI:10.1126/science.286.5439.498
51. A.C.Conibear, K.J.Rosengren, P.J.Harvey, et al. Structural characterization of the cyclic cystine ladder motif of θ-defensins. Biochemistry. 2012;51:9718–97126. DOI:10.1021/bi301363a
52. A.C.Conibear, K.J.Rosengren, N.L.Daly, et al. The cyclic cystine ladder in theta-defensins is important for structure and stability, but not antibacterial activity. J Biol Chem. 2013;288:10830–10840. DOI:10.1074/jbc.M113.451047
53. A.C.Conibear, D.J.Craik. The chemistry and biology of theta defensins. Angew Chem Int Ed Engl. 2014;53:10612–10623. DOI:10.1002/anie.201402167
54. P.Tongaonkar, P.Tran, K.Roberts, et al. Rhesus macaque theta-defensin isoforms:expression, antimicrobial activities, and demonstration of a prominent role in neutrophil granule microbicidal activities. J Leukoc Biol. 2011;89:283–290. DOI:10.1189/jlb.0910535
55. J.B.Schaal, D.Tran, P.Tran, et al. Rhesus macaque theta defensins suppress inflammatory cytokines and enhance survival in mouse models of bacteremic sepsis. PLoS One. 2012;7:e51337. DOI:10.1371/journal.pone.0051337
56. M.Wilmes, M.Stockem, G.Bierbaum, et al. Killing of staphylococci by θ-defensins involves membrane impairment and activation of autolytic enzymes. Antibiotics. 2014;3:617–631. DOI:10.3390/antibiotics3040617
57. P.Tongaonkar, K.K.Trinh, J.B.Schaal, et al. Rhesus macaque theta-defensin RTD-1 inhibits proinflammatory cytokine secretion and gene expression by inhibiting the activation of NF-kappaB and MAPK pathways. J Leukoc Biol. 2015;98:1061–1070. DOI:10.1189/jlb.3A0315-102R
58. C.L.Wohlford-Lenane, D.K.Meyerholz, S.Perlman, et al. Rhesus theta-defensin prevents death in a mouse model of severe acute respiratory syndrome coronavirus pulmonary disease. J Virol. 2009;83:11385–11390. DOI:10.1128/jvi.01363-09
59. Y.T.Oh, D.Tran, T.A.Buchanan, et al. theta-Defensin RTD-1 improves insulin action and normalizes plasma glucose and FFA levels in diet-induced obese rats. Am J Physiol Endocrinol Metab. 2015;309:e154–160. DOI:10.1152/ajpendo.00131.2015
60. A.M.Cole, T.Hong, L.M.Boo, et al. Retrocyclin:A primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. Proc Natl Acad Sci USA. 2002;99:1813–1818. DOI:10.1073/pnas.052706399
61. C.Yang, L.Boone, T.X.Nguyen, et al. Theta-defensin pseudogenes in HIV-1-exposed, persistently seronegative female sex-workers from Thailand. Infect Genet Evol. 2005;5:11–15. DOI:10.1016/j.meegid.2004.05.006
62. A.C.Conibear, A.Bochen, K.J.Rosengren, et al. The cyclic cystine ladder of theta-defensins as a stable, bifunctional scaffold:a proof-of-concept study using the integrin-binding RGD motif. ChemBioChem. 2014;15:451–459. DOI:10.1002/cbic.201300568• The first paper demonstrating the use of θ-defensins as a stable scaffold for the grafting of bioactive epitopes.
63. T.L.Aboye, H.Ha, S.Majumder, et al. Design of a novel cyclotide-based CXCR4 antagonist with anti-Human Immunodeficiency Virus (HIV)-1 activity. J Med Chem. 2012;55:10729–10734. DOI:10.1021/jm301468k
64. A.C.Conibear, S.Chaousis, T.Durek, et al. Approaches to the stabilization of bioactive epitopes by grafting and peptide cyclization. Biopolymers. 2016;106:89–100. DOI:10.1002/bip.22767
65. S.Luckett, R.S.Garcia, J.J.Barker, et al. High-resolution structure of a potent, cyclic proteinase inhibitor from sunflower seeds. J Mol Biol. 1999;290:525–533. DOI:10.1006/jmbi.1999.2891
66. A.G.Elliott, C.Delay, H.Liu, et al. Evolutionary origins of a bioactive peptide buried within preproalbumin. Plant Cell. 2014;26:981–995. DOI:10.1105/tpc.114.123620
67. R.F.Qi, Z.W.Song, C.W.Chi. Structural features and molecular evolution of bowman-birk protease inhibitors and their potential application. Acta Biochim Biophys Sinica. 2005;37:283–292. DOI:10.1111/j.1745-7270.2005.00048.x
68. M.L.Korsinczky, R.J.Clark, D.J.Craik. Disulfide bond mutagenesis and the structure and function of the head-to-tail macrocyclic trypsin inhibitor SFTI-1. Biochemistry. 2005;44:1145–1153. DOI:10.1021/bi048297r
69. D.J.Craik, J.E.Swedberg, J.S.Mylne, et al. Cyclotides as a basis for drug design. Exp Opin Drug Disc. 2012;7:179–194. DOI:10.1517/17460441.2012.661554
70. L.Y.Chan, D.J.Craik, N.L.Daly. Cyclic thrombospondin-1 mimetics:grafting of a thrombospondin sequence into circular disulfide-rich frameworks to inhibit endothelial cell migration. Biosci Rep. 2015;35. DOI:10.1042/bsr20150210
71. C.K.Wang, S.E.Northfield, Y.H.Huang, et al. Inhibition of tau aggregation using a naturally-occurring cyclic peptide scaffold. Euro J Med Chem. 2016;109:342–349. DOI:10.1016/j.ejmech.2016.01.006
72. S.J.De Veer, J.E.Swedberg, M.Akcan, et al. Engineered protease inhibitors based on sunflower trypsin inhibitor-1 (SFTI-1) provide insights into the role of sequence and conformation in Laskowski mechanism inhibition. Biochem J. 2015;469:243–253. DOI:10.1042/bj20150412
73. H.Fittler, A.Depp, O.Avrutina, et al. Engineering a constrained peptidic scaffold towards potent and selective furin inhibitors. ChemBioChem. 2015;16:2441–2444. DOI:10.1002/cbic.201500447
74. C.Jendrny, A.G.Beck-Sickinger. Inhibition of kallikrein-related peptidases 7 and 5 by grafting serpin reactive-center loop sequences onto sunflower trypsin inhibitor-1 (SFTI-1). ChemBioChem. 2015;17:719–726. DOI:10.1002/cbic.201500539
75. J.E.Swedberg, L.V.Nigon, J.C.Reid, et al. Substrate-guided design of a potent and selective kallikrein-related peptidase inhibitor for kallikrein 4. Chem Biol. 2009;16:633–643. DOI:10.1016/j.chembiol.2009.05.008
76. D.P.Okinyo-Owiti, Q.Dong, B.Ling, et al. Evaluating the cytotoxicity of flaxseed orbitides for potential cancer treatment. Toxicol Rep. 2015;2:1014–1018. DOI:10.1016/j.toxrep.2015.06.011
77. T.J.Gaymes, M.Cebrat, I.Z.Siemion, et al. Cyclolinopeptide A (CLA) mediates its immunosuppressive activity through cyclophilin-dependent calcineurin inactivation. FEBS Letters. 1997;418:224–227. DOI:10.1016/S0014-5793(97)01345-8
78. J.Katarzyńska, A.Mazur, E.Rudzińska, et al. Cyclolinopeptide derivatives modify methotrexate-induced suppression of the humoral immune response in mice. Euro J Med Chem. 2011;46:4608–4617. DOI:10.1016/j.ejmech.2011.07.040
79. C.P.Scott, E.Abel-Santos, M.Wall, et al. Production of cyclic peptides and proteins in vivo. Proc Natl Acad Sci USA. 1999;96:13638–13643. DOI:10.1073/pnas.96.24.13638
80. J.M.Smith, J.R.Frost, R.Fasan. Emerging strategies to access peptide macrocycles from genetically encoded polypeptides. J Org Chem. 2013;78:3525–3531. DOI:10.1021/jo400119s
81. T.Passioura, T.Katoh, Y.Goto, et al. Selection-based discovery of druglike macrocyclic peptides. Annu Rev Biochem. 2014;83:727–752. DOI:10.1146/annurev-biochem-060713-035456
82. K.R.Lennard, A.Tavassoli. Peptides come round:using SICLOPPS libraries for early stage drug discovery. Chemistry. 2014;20:10608–10614. DOI:10.1002/chem.201403117
83. R.J.Clark, H.Fischer, L.Dempster, et al. Engineering stable peptide toxins by means of backbone cyclization:stabilization of the alpha-conotoxin MII. Proc Natl Acad Sci USA. 2005;102:13767–13772. DOI:10.1073/pnas.0504613102
84. R.J.Clark, J.Jensen, S.T.Nevin, et al. The engineering of an orally active conotoxin for the treatment of neuropathic pain. Angew Chem Int Ed. 2010;49:6545–6548. DOI:10.1002/anie.201000620
85. B receptor. J Med Chem. 2011;54:6984–6992. DOI:10.1021/jm201060r
86. C.J.Armishaw, J.L.Dutton, D.J.Craik, et al. Establishing regiocontrol of disulfide bond isomers of alpha-conotoxin ImI via the synthesis of N-to-C cyclic analogs. Biopolymers. 2010;94:307–313. DOI:10.1002/bip.21360
87. C.J.Armishaw, A.A.Jensen, L.D.Balle, et al. Improving the stability of alpha-conotoxin AuIB through N-to-C cyclization:the effect of linker length on stability and activity at nicotinic acetylcholine receptors. Antioxid Redox Signal. 2011;14:65–76. DOI:10.1089/ars.2010.3458
88. E.S.Lovelace, S.Gunasekera, C.Alvarmo, et al. Stabilization of alpha-conotoxin AuIB:influences of disulfide connectivity and backbone cyclization. Antioxid Redox Signal. 2011;14:87–95. DOI:10.1089/ars.2009.3068
89. E.S.Lovelace, C.J.Armishaw, M.L.Colgrave, et al. Cyclic MrIA:A stable and potent cyclic conotoxin with a aovel topological fold that targets the norepinephrine transporter. J Med Chem. 2006;49:6561–6568. DOI:10.1021/jm060299h
90. X.Hemu, M.Taichi, Y.Qiu, et al. Biomimetic synthesis of cyclic peptides using novel thioester surrogates. Biopolymers. 2013;100:492–501. DOI:10.1002/bip.22308
91. M.Akcan, R.J.Clark, N.L.Daly, et al. Transforming conotoxins into cyclotides:backbone cyclization of P-superfamily conotoxins. Biopolymers. 2015;104:682–692. DOI:10.1002/bip.22699
92. L.Y.Chan, V.M.Zhang, Y.H.Huang, et al. Cyclization of the antimicrobial peptide gomesin with native chemical ligation:influences on stability and bioactivity. ChemBioChem. 2013;14:617–624. DOI:10.1002/cbic.201300034
93. J.E.Jensen, M.Mobli, A.Brust, et al. Cyclisation increases the stability of the sea anemone peptide APETx2 but decreases its activity at acid-sensing ion channel 3. Marine Drugs. 2012;10:1511–1527. DOI:10.3390/md10071511
94. R.J.Clark, G.C.Preza, C.C.Tan, et al. Design, synthesis, and characterization of cyclic analogues of the iron regulatory peptide hormone hepcidin. Biopolymers. 2013;100:519–526. DOI:10.1002/bip.22350
95. M.J.Scanlon, D.Naranjo, L.Thomas, et al. Solution structure and proposed binding mechanism of a novel potassium channel toxin κ-conotoxin PVIIA. Structure. 1997;5:1585–1597. DOI:10.1016/S0969-2126(97)00307-9
96. S.Kwon, F.Bosmans, Q.Kaas, et al. Efficient enzymatic cyclization of an inhibitory cystine knot-containing peptide. Biotechnol Bioeng. 2016;113:2202–2212. DOI:10.1002/bit.25993
97. P.Timmerman, J.Beld, W.C.Puijk, et al. Rapid and quantitative cyclization of multiple peptide loops onto synthetic scaffolds for structural mimicry of protein surfaces. ChemBioChem. 2005;6:821–824. DOI:10.1002/cbic.200400374
98. S.Chen, J.Morales-Sanfrutos, A.Angelini, et al. Structurally diverse cyclisation linkers impose different backbone conformations in bicyclic peptides. ChemBioChem. 2012;13:1032–1038. DOI:10.1002/cbic.201200049
99. S.Chen, D.Bertoldo, A.Angelini, et al. Peptide ligands stabilized by small molecules. Angew Chem Int Ed Engl. 2014;53:1602–1606. DOI:10.1002/anie.201309459•• An article highlighting the use of small organic molecules to stabilize peptide epitopes through noncovalent bonding interactions.
100. C.Heinis, G.Winter. Encoded libraries of chemically modified peptides. Curr Opin Chem Biol. 2015;26:89–98. DOI:10.1016/j.cbpa.2015.02.008•• A review highlighting the development of peptides with topological constraints using DNA-encoded protein libraries.
101. C.Heinis, T.Rutherford, S.Freund, et al. Phage-encoded combinatorial chemical libraries based on bicyclic peptides. Nat Chem Biol. 2009;5:502–507. DOI:10.1038/nchembio.184
102. V.Baeriswyl, H.Rapley, L.Pollaro, et al. Bicyclic peptides with optimized ring size inhibit human plasma kallikrein and its orthologues while sparing paralogous proteases. ChemMedChem. 2012;7:1173–1176. DOI:10.1002/cmdc.201200071
103. V.Baeriswyl, S.Calzavarini, S.Chen, et al. A synthetic factor XIIa inhibitor blocks selectively intrinsic coagulation initiation. ACS Chem Biol. 2015;10:1861–1870. DOI:10.1021/acschembio.5b00103• An article outlining the use of a constrained bicyclic peptide to potently and selectively inhibit coagulation factor XIIa.
104. D.Bertoldo, M.M.G.Khan, P.Dessen, et al. Phage selection of peptide macrocycles against β-catenin to interfere with Wnt signaling. ChemMedChem. 2016;11:834–839. DOI:10.1002/cmdc.201500557• A paper demonstrating the use of constrained bicyclic peptides to target β-catenin interfering with the Wnt signaling pathway involved in tumor formation.
105. L.Pollaro, S.Raghunathan, J.Morales-Sanfrutos, et al. Bicyclic peptides conjugated to an albumin-binding tag diffuse efficiently into solid tumors. Mol Cancer Ther. 2015;14:151–161. DOI:10.1158/1535-7163.MCT-14-0534
106. R.Wallbrecher, L.Depré, W.P.R.Verdurmen, et al. Exploration of the design principles of a cell-penetrating bicylic peptide scaffold. Bioconjugate Chem. 2014;25:955–964. DOI:10.1021/bc500107f•• An article highlighting the structural parameters for cell penetration of constrained bicyclic peptides.
107. C.E.Schafmeister, J.Po, G.L.Verdine. An all-hydrocarbon cross-linking system for enhancing the helicity and metabolic stability of peptides. J Am Chem Soc. 2000;122:5891–5892. DOI:10.1021/ja000563a• The first paper reporting the development of a stapled peptide.
108. Aileron therapeutics successfully completes first-ever stapled peptide clinical trial. Business Wire. Cambridge, MA:Aileron Therapeutics, 2013; [cited 2016 Jul12]. Available from:http://www.businesswire.com/news/home/20130507005467/en/Aileron-Therapeutics-Successfully-Completes-First-Ever-Stapled-Peptide
109. Aileron therapeutics initiates phase 1 cancer study of ALRN-6924 in advanced hematologic and solid malignancies with wild type p53. Business Wire. Cambridge, MA:Aileron Therapeutics; 2015 [cited 2016 Jul12]. Available from:http://www.businesswire.com/news/home/20150212005199/en/Aileron-Therapeutics-Initiates-Phase-1-Cancer-Study
110. T.Okamoto, K.Zobel, A.Fedorova, et al. Stabilizing the pro-apoptotic BimBH3 helix (BimSAHB) does not necessarily enhance affinity or biological activity. ACS Chem Biol. 2013;8:297–302. DOI:10.1021/cb3005403
111. Y.C.Li, L.W.Rodewald, C.Hoppmann, et al. A versatile platform to analyze low-affinity and transient protein-protein interactions in living cells in real time. Cell Rep. 2014;9:1946–1958. DOI:10.1016/j.celrep.2014.10.058• A paper describing a method to analyze weak intracellular protein–protein interactions in real time and its application assessing the cellular permeability of selected stapled peptides.
112. P.M.Cromm, J.Spiegel, T.N.Grossmann. Hydrocarbon stapled peptides as modulators of biological function. ACS Chem Biol. 2015;10:1362–1375. DOI:10.1021/cb501020r• A review highlighting the development and applications of hydrocarbon stapled peptides in drug discovery.
113. Q.Chu, R.E.Moellering, G.J.Hilinski, et al. Towards understanding cell penetration by stapled peptides. MedChemComm. 2015;6:111–119. DOI:10.1039/C4MD00131A• A paper investigating the structural features associated with cell-penetrating properties of stapled peptides.
114. E.S.Leshchiner, C.R.Braun, G.H.Bird, et al. Direct activation of full-length proapoptotic BAK. Proc Natl Acad Sci USA. 2013;110:e986–995. DOI:10.1073/pnas.1214313110
115. G.H.Bird, E.Gavathiotis, J.L.LaBelle, et al. Distinct BimBH3 (BimSAHB) stapled peptides for structural and cellular studies. ACS Chem Biol. 2014;9:831–837. DOI:10.1021/cb4003305•• An article highlighting the key design considerations in the development of stapled peptides.
116. F.Bernal, M.Wade, M.Godes, et al. A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell. 2010;18:411–422. DOI:10.1016/j.ccr.2010.10.024• A study using phage display in the development of a stapled peptide that selectively inhibits Mdm2/Mdm4 in the activation of the p53 tumor suppression protein.
117. C.J.Brown, S.T.Quah, J.Jong, et al. Stapled peptides with improved potency and specificity that activate p53. ACS Chem Biol. 2013;8:506–512. DOI:10.1021/cb3005148
118. Y.S.Chang, B.Graves, V.Guerlavais, et al. Stapled α-helical peptide drug development:a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc Natl Acad Sci USA. 2013;110:e3445–3454. DOI:10.1073/pnas.1303002110•• A paper reporting the use of a stapled peptide that targets the overexpression of inhibitory proteins MDM2 and MDMX to reactivate the p53 tumor suppressor protein in vivo.
119. Y.Q.Long, S.X.Huang, Z.Zawahir, et al. Design of cell-permeable stapled peptides as HIV-1 integrase inhibitors. J Med Chem. 2013;56:5601–5612. DOI:10.1021/jm4006516
120. C.Phillips, L.R.Roberts, M.Schade, et al. Design and structure of stapled peptides binding to estrogen receptors. J Am Chem Soc. 2011;133:9696–9699. DOI:10.1021/ja202946k
121. G.H.Bird, E.Mazzola, K.Opoku-Nsiah, et al. Biophysical determinants for cellular uptake of hydrocarbon-stapled peptide helices. Nat Chem Biol. 2016;12:845–852.•• A paper outlining the key design principles in the development of cell-permeable stapled peptides.
122. M.Pelay-Gimeno, A.Glas, O.Koch, et al. Structure-based design of inhibitors of protein–protein interactions:mimicking peptide binding epitopes. Angew Chem Int Ed. 2015;54:8896–8927. DOI:10.1002/anie.201412070• A review that outlines current approaches in the development of various classes of peptide mimetics targeting protein–protein interactions.
123. D.Obrecht, E.Chevalier, K.Moehle, et al. β-Hairpin protein epitope mimetic technology in drug discovery. Drug Discov Today Technol. 2012;9:e63–69. DOI:10.1016/j.ddtec.2011.07.006
124. J.Späth, F.Stuart, L.Jiang, et al. Stabilization of a β-hairpin conformation in a cyclic peptide using the templating effect of a heterochiral diproline unit. Helvetica Chimica Acta. 1998;81:1726–1738. DOI:10.1002/(SICI)1522-2675(19980909)81:9<1726::AID-HLCA1726>3.0.CO;2-H
125. J.Schmidt, K.Patora-Komisarska, K.Moehle, et al. Structural studies of β-hairpin peptidomimetic antibiotics that target LptD in Pseudomonas sp. Bioorg Med Chem. 2013;21:5806–5810. DOI:10.1016/j.bmc.2013.07.013
126. N.Srinivas, P.Jetter, B.J.Ueberbacher, et al. Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa. Science. 2010;327:1010–1013. DOI:10.1126/science.1182749• A paper reporting the development of a β-hairpin peptidomimetic as an antimicrobial agent against the pathogen Pseudomonas spp. with a novel mode of action.
127. S.U.Vetterli, K.Moehle, J.A.Robinson. Synthesis and antimicrobial activity against Pseudomonas aeruginosa of macrocyclic β-hairpin peptidomimetic antibiotics containing N-methylated amino acids. Bioorg Med Chem. 2016. DOI:10.1016/j.bmc.2016.05.027
128. M.Urfer, J.Bogdanovic, F.Lo Monte, et al. A peptidomimetic antibiotic targets outer membrane proteins and disrupts selectively the outer membrane in escherichia coli. J Biol Chem. 2016;291:1921–1932. DOI:10.1074/jbc.M115.691725•• An article describing the development of a β-hairpin peptidomimetic that selectively targets outer membrane β-barrel proteins in E. coli.
129. R.Fasan, R.L.Dias, K.Moehle, et al. Using a beta-hairpin to mimic an alpha-helix:cyclic peptidomimetic inhibitors of the p53-HDM2 protein-protein interaction. Angew Chem Int Ed Engl. 2004;43:2109–2112. DOI:10.1002/anie.200353242
130. R.Fasan, R.L.Dias, K.Moehle, et al. Structure-activity studies in a family of beta-hairpin protein epitope mimetic inhibitors of the p53-HDM2 protein-protein interaction. ChemBioChem. 2006;7:515–526. DOI:10.1002/cbic.200500452
131. T.A.Hill, R.-J.Lohman, H.N.Hoang, et al. Cyclic penta- and hexaleucine peptides without N-methylation are orally absorbed. ACS Med Chem Lett. 2014;5:1148–1151. DOI:10.1021/ml5002823
132. D.S.Nielsen, H.N.Hoang, R.-J.Lohman, et al. Improving on nature:making a cyclic heptapeptide orally bioavailable. Angew Chem Int Ed. 2014;53:12059–12063. DOI:10.1002/anie.201405364•• A study that investigates the effects of heterocyclic constraints, intermolecular hydrogen bonds, and side-chain interactions in the development of orally bioavailable cyclic peptides.
133. T.R.White, C.M.Renzelman, A.C.Rand, et al. On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds. Nat Chem Biol. 2011;7:810–817. DOI:10.1038/nchembio.664• A paper describing a method for on-resin N-methylation and its application for the development of orally bioavailable N-methylated cyclic peptides.
134. J.G.Beck, J.Chatterjee, B.Laufer, et al. Intestinal permeability of cyclic peptides:common key backbone motifs identified. J Am Chem Soc. 2012;134:12125–12133. DOI:10.1021/ja303200d• Along with reference 135, highlights the backbone structural characteristics of orally bioavailable cyclic peptides containing both N-methylated and D-amino acid residues.
135. U.K.Marelli, O.Ovadia, A.O.Frank, et al. cis-peptide bonds:A key for intestinal permeability of peptides? Chem Euro J. 2015;21:15148–15152. DOI:10.1002/chem.201501600
136. D.S.Nielsen, R.-J.Lohman, H.N.Hoang, et al. Flexibility versus rigidity for orally bioavailable cyclic hexapeptides. ChemBioChem. 2015;16:2289–2293. DOI:10.1002/cbic.201500441
137. A.T.Bockus, K.W.Lexa, C.R.Pye, et al. Probing the physicochemical boundaries of cell permeability and oral bioavailability in lipophilic macrocycles inspired by natural products. J Med Chem. 2015;58:4581–4589. DOI:10.1021/acs.jmedchem.5b00128
138. A.T.Bockus, J.A.Schwochert, C.R.Pye, et al. Going out on a limb:delineating the effects of beta-branching, N-methylation, and side chain size on the passive permeability, solubility, and flexibility of sanguinamide A analogues. J Med Chem. 2015;58:7409–7418. DOI:10.1021/acs.jmedchem.5b00919